Related Experiment Videos
A collaborative approach to home OKT3 infusion therapy
P A Campbell1, C M Runner-Heidt
1Lehigh Valley Hospital Transplant Program, Lehigh Valley Hospital, Allentown, PA.
The Journal of Nursing Administration
|November 1, 1993
Summary
Renal transplant patients can receive complex antirejection therapy at home. This home-based Muromonab-CD3 (OKT3) infusion program reduces hospitalization costs and maintains quality care.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pharmacology
Background:
- Prolonged hospitalization for renal transplant recipients is common due to antirejection infusion therapy.
- High hospitalization costs necessitate alternative care delivery models.
- Outpatient settings are being explored for complex post-transplant management.
Purpose of the Study:
- To describe the implementation of a home-based intravenous Muromonab-CD3 (OKT3) administration program.
- To evaluate the feasibility and effectiveness of outpatient antirejection therapy for renal transplant patients.
Main Methods:
- Development of a structured home care program for Muromonab-CD3 (OKT3) infusions.
- Close collaboration between transplant services and home care providers.
- Focus on thorough planning and patient selection for home therapy.
Main Results:
- Successful implementation of a home-based Muromonab-CD3 (OKT3) infusion program.
- Facilitation of quality care in an outpatient setting for renal transplant recipients.
- Potential for reduced hospitalization duration and associated costs.
Conclusions:
- Home-based intravenous Muromonab-CD3 (OKT3) therapy is an effective strategy for renal transplant recipients.
- Careful planning and interdisciplinary collaboration are crucial for successful outpatient infusion programs.
- This model supports quality post-transplant care while potentially reducing healthcare expenditures.